Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells

(2014) Harris Wang et al.   BMC CANCER

STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice

(2013) Florence Meyer-Losic et al.   PLoS One

Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies

(2012) S. Murray et al.   CANCER TREATMENT REVIEWS

An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

(2012) Yan Lu et al.   PHARMACEUTICAL RESEARCH

Mitosis-targeted anti-cancer therapies: where they stand

(2012) K-S Chan et al.   Cell Death & Disease

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The hematopoietic-specific β1-tubulin is naturally resistant to 2-Methoxyestradiol and protects patients from drug-induced myelosuppression

(2011) Daniel Escuin et al.   CELL CYCLE

Overcoming Taxane and Anthracycline Resistance

(2010) Amelia Zelnak   Breast Journal

Implications of Anthracycline-Resistant and Taxane-Resistant Metastatic Breast Cancer and New Therapeutic Options

(2010) Edgardo Rivera   Breast Journal

Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review

(2010) Suman Lal et al.   CURRENT DRUG METABOLISM

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Regulation of EGF-Stimulated EGF Receptor Endocytosis During M Phase

(2010) Lei Liu et al.   TRAFFIC

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents

(2009) C Stengel et al.   BRITISH JOURNAL OF CANCER

How do anti-mitotic drugs kill cancer cells?

(2009) K. E. Gascoigne et al.   JOURNAL OF CELL SCIENCE